Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response

被引：0
|
作者：
Rossi, Giovanni [1 ]
Genova, Carlo [1 ]
Morbelli, Silvia [2 ]
Rijavec, Erka [1 ]
Barletta, Giulia [1 ]
Biello, Federica [1 ]
Maggioni, Claudia [1 ]
Mennella, Simone [3 ]
Dal Bello, Maria Giovanna [1 ]
Distefano, Roberta [1 ]
Bauckneht, Matteo [2 ]
Cittadini, Giuseppe [3 ]
Merlo, Franco [1 ]
Sambuceti, Gianmario [2 ]
Grossi, Francesco [1 ]
机构：
[1] San Martino Hosp, Natl Inst Canc Res, Lung Canc Unit, Genoa, Italy
[2] San Martino Hosp, Natl Inst Canc Res, Nucl Med, Genoa, Italy
[3] San Martino Hosp, Natl Inst Canc Res, Radiol, Genoa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
response evaluation; Nivolumab; PERCIST; RECIST;
D O I：
10.1016/j.jtho.2016.11.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA10.09
引用
收藏
页码：S401 / S402
页数：2
相关论文
共 50 条
  • [1] Comparison between CT scan evaluation criteria and PERCIST for evaluation of immune check-point inhibitors response
    Rossi, G.
    Genova, C.
    Morbelli, S.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Maggioni, C.
    Mennella, S.
    Dal Bello, M. G.
    Distefano, R.
    Bauckneht, M.
    Tagliamento, M.
    Cittadini, G.
    Merlo, D. F.
    Sambuceti, G.
    Grossi, F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 162 - 162
  • [2] Comparison between PERCIST and EORTC criteria in the evaluation of response to immune check-point inhibitors in Non-Small Cell Lung Cancer (NSCLC) patients
    Piva, R.
    Rossi, G.
    Bauckneht, M.
    Genova, C.
    Ceriani, V.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Calamia, I.
    Dal Bello, G.
    Di Stefano, R.
    Sambuceti, G.
    Grossi, F.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S674 - S674
  • [3] Cholangiocarcinoma: Era of Immune Check-Point Inhibitors
    El Hag, Mohamed I.
    Wood-Trageser, Michelle
    Patel, Krishna
    Specht, Susan
    Sasatomi, Eizaburo
    Sun, Weijing
    Demetris, Anthony
    MODERN PATHOLOGY, 2018, 31 : 633 - 633
  • [4] Cholangiocarcinoma: Era of Immune Check-Point Inhibitors
    El Hag, Mohamed I.
    Wood-Trageser, Michelle
    Patel, Krishna
    Specht, Susan
    Sasatomi, Eizaburo
    Sun, Weijing
    Demetris, Anthony
    LABORATORY INVESTIGATION, 2018, 98 : 633 - 633
  • [5] Assessment of the Prognostic value of PERCIST 1.0 and Simplified PERCIST ("SPERCIST")" FDG PET in Patients with Advanced Melanoma Treated with Immune Check-point Inhibitors
    Lee, Min-Young
    Crandall, John
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [6] Proton pump inhibitors and response to immune check-point inhibitors: Single center study.
    Trabolsi, Asaad
    Winter, Megan
    Rodriquez, Estelamari
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Targeted Interleukin 2 and synergy with immune check-point inhibitors
    Hutmacher-Berndt, Cornelia Deborah
    Neri, Dario
    CANCER RESEARCH, 2018, 78 (13)
  • [8] MYOCARDITIS SECONDARY TO IMMUNE CHECK-POINT INHIBITORS: DIFFICULTIES IN ARRHYTHMIA MANAGEMENT
    Stringer, Bryan F.
    Kethireddy, Nikhila
    Rizkallah, Alain
    Darsaklis, Konstadina
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 2694 - 2694
  • [9] Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
    Soares, Adriana
    Carmo, Rafael
    Rodrigues, Catarina
    Grilo, Ines Teles
    Grande, Enrique
    BLADDER CANCER, 2020, 6 (01) : 1 - 8
  • [10] Comparison between CT-based and PERCIST criteria for evaluation of response to immune checkpoint inhibitors in Non-Small Cell Lung Cancer (NSCLC): is there a role for 18F-FDG PET/CT?
    Bauckneht, M.
    Rossi, G.
    Piva, R.
    Genova, C.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Menella, S.
    Dal Bello, M.
    Di Stefano, R.
    Cittadini, G.
    Merlo, D.
    Sambuceti, G.
    Grossi, F.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S51 - S51
12345